ArticleClinical ophthalmology (Auckland, N.Z.)2019
Ab interno canaloplasty combined with trabecular bypass stenting in eyes with primary open-angle glaucoma.
Article in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Visual Function After Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2025Review
- From first generation to the next: evolution and research trends in iStent technology.Frontiers in medicine · 2025Review
- Efficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Meta-Analysis of MINIject vs. Two iStents as Standalone Treatment for Glaucoma with 24 Months of Follow-Up.Journal of clinical medicine · 2024Review
- Evaluating the 1-year success and safety of ab interno canaloplasty in combination with cataract surgery in glaucoma patients.International ophthalmology · 2024Article
- Comparative Effectiveness and Safety of Two Different Trabecular MIGS Devices With and Without Ab Interno Canaloplasty in Patients with Primary Open-Angle Glaucoma.Ophthalmology and therapy · 2023Article
- Efficacy and Safety of Pairing iStent Inject Trabecular Micro-Bypass and iAccess Precision Blade Goniotomy in Patients with Open-Angle Glaucoma.Ophthalmology and therapy · 2023Article
- Hydrus Microstent implantation with OMNI Surgical System Ab interno canaloplasty for the management of open-angle glaucoma in phakic patients refractory to medical therapy.American journal of ophthalmology case reports · 2023Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Canaloplasty for the treatment of primary open-angle glaucoma: A protocol of systematic review and meta-analysis.Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvaluate outcomes of trabecular meshwork (TM) bypass (iStent
settingPrivate surgical center for a comprehensive ophthalmology practice.
designRetrospective analysis of 186 eyes from 130 consecutive patients with 6 months follow-up.
methodsEligible eyes had POAG, indicated for CE, and had received CE + TM-bypass or CE + TM-bypass + CP. Exclusions: glaucomas not POAG, SLT within 6 months, or previous ALT. IOP, visual acuity, and medication use assessed at baseline, months 1, 3, and 6. Endpoints were mean reduction in IOP from baseline at 6 months, proportion with IOP reduction at 6 months of ≥20% and IOP <18 mmHg on same or fewer medications, mean medication reduction, and proportion medication independent.
resultsEighty-six eyes comprised the CE + TM-bypass + CP group; 100 eyes in the CE + TM-bypass group. At 6 months: mean IOP reduction was 2.9±3.6 mmHg for CE + TM-bypass + CP and 1.7±3.1 mmHg for CE + TM-bypass group (
conclusionAt six months, a greater proportion of CE + TM-bypass + CP patients achieved IOP reduction of ≥20% and an IOP <18 mmHg on the same or fewer medications than for TM-bypass + CE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.